However, another investigation into CTNNB1 mutations in HCC patients revealed that lower CTNNB1 expression was associated with improved overall survival (OS), particularly in patients treated with ICIs or tyrosine kinase inhibitors (TKI), highlighting the potential of CTNNB1 expression as a biomarker for treatment selection (48). Here, CTNNB1 is linked to hepatocellular carcinoma.